Table 3.
Hazard ratios for mortality by the serum uric acid levels at baseline.
| Serum uric acid (mg/dL) | No. of events | All-cause mortality | No. of events | Cardiovascular mortality | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Men (No. of subjects) | Unadjusted HR (95%CI) | P value | Adjusted HR (95%CI)* | P value | Unadjusted HR (95%CI) | P value | Adjusted HR (95%CI)* | P value | ||
| <2.9 (1,992) | 57 | 1.86 (1.42–2.43) | <0.01 | 1.49 (1.12–1.98) | <0.01 | 13 | 2.47 (1.38–4.44) | <0.01 | 2.51 (1.36–4.62) | <0.01 |
| 3.0–3.9 (9,449) | 210 | 1.42 (1.22–1.64) | <0.01 | 1.15 (0.97–1.36) | 0.10 | 31 | 1.19 (0.78–1.81) | 0.42 | 1.22 (0.79–1.87) | 0.37 |
| 4.0–4.9 (30,383) | 554 | 1.17 (1.05–1.30) | <0.01 | reference | 82 | reference | reference | |||
| 5.0–5.9 (60,311) | 1,013 | 1.08 (0.99–1.18) | 0.10 | 1.06 (0.95–1.19) | 0.26 | 193 | 1.19 (0.92–1.55) | 0.19 | 1.29 (0.98–1.69) | 0.07 |
| 6.0–6.9 (61,317) | 946 | reference | 1.06 (0.95–1.19) | 0.30 | 189 | 1.16 (0.89–1.50) | 0.27 | 1.22 (0.92–1.62) | 0.17 | |
| 7.0–7.9 (34,764) | 539 | 1.01 (0.91–1.13) | 0.81 | 1.18 (1.04–1.35) | 0.01 | 133 | 1.49 (1.10–1.91) | <0.01 | 1.72 (1.27–2.32) | <0.01 |
| 8.0–8.9 (12,605) | 254 | 1.34 (1.16–1.54) | <0.01 | 1.70 (1.45–2.00) | <0.01 | 72 | 2.22 (1.62–3.06) | <0.01 | 2.58 (1.81–3.66) | <0.01 |
| > 9.0 (4,907) | 176 | 2.44 (2.08–2.87) | <0.01 | 3.11 (2.58–3.76) | <0.01 | 49 | 3.88 (2.72–5.55) | <0.01 | 3.99 (2.63–6.04) | <0.01 |
| Hyperuricemia (>7 mg/dL) (47,443) | 891 | 1.14 (1.05–1.23) | <0.01 | 1.39 (1.28–1.51) | <0.01 | 234 | 1.62 (1.39–1.89) | <0.01 | 1.68 (1.41–2.00) | <0.01 |
| Women (No. of subjects) | No. of events | Unadjusted HR (95%CI) | P value | Adjusted HR (95%CI)* | P value | No. of events | Unadjusted HR (95%CI) | P value | Adjusted HR (95%CI)* | P value |
| <2.9 (11,753) | 103 | 1.57 (1.27–1.93) | <0.01 | 1.52 (1.22–1.90) | <0.01 | 15 | 1.49 (0.87–2.58) | 0.15 | 1.53 (0.87–2.73) | 0.14 |
| 3.0–3.9 (59,448) | 358 | 1.07 (0.94–1.23) | 0.28 | 1.05 (0.91–1.21) | 0.51 | 61 | 1.20 (0.87–1.67) | 0.26 | 1.13 (0.80–1.61) | 0.49 |
| 4.0–4.9 (107,025) | 592 | reference | reference | 90 | reference | reference | ||||
| 5.0–5.9 (72,205) | 461 | 1.19 (1.05–1.35) | 0.01 | 1.20 (1.06–1.37) | <0.01 | 108 | 1.80 (1.36–2.89) | <0.01 | 1.71 (1.27–2.30) | <0.01 |
| 6.0–6.9 (25,762) | 208 | 1.58 (1.35–1.86) | <0.01 | 1.50 (1.26–1.78) | <0.01 | 40 | 1.99 (1.37–2.89) | <0.01 | 1.52 (1.00–2.30) | 0.051 |
| 7.0–7.9 (6,625) | 65 | 1.99 (1.54–2.58) | <0.01 | 1.85 (1.40–2.46) | <0.01 | 15 | 3.00 (1.74–5.18) | <0.01 | 1.93 (1.01–3.68) | 0.047 |
| > 8.0 (1,965) | 42 | 4.53 (3.30–6.22) | <0.01 | 3.84 (2.68–5.52) | <0.01 | 13 | 9.31 (5.20–16.6) | <0.01 | 6.45 (3.32–12.5) | <0.01 |
| Hyperuricemia (>7 mg/dL) (7,359) | 90 | 2.17 (1.75–2.69) | <0.01 | 1.95 (1.54–2.47) | <0.01 | 26 | 3.48 (2.33–5.19) | <0.01 | 2.49 (1.57–3.93) | <0.01 |
*Adjusted for age, body mass index, smoking, alcohol consumption, eGFR, systolic blood pressure, HbA1c (NGSP), triglycerides, HDL-cholesterol, LDL-cholesterol, antihypertensive medication, antidiabetic medication, lipid-lowering medication.
eGFR; estimated glomerular filtration rate, HR; hazard ratio, CI; confidence interval.